Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248570 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
A Phase 2 study of Metastatic Prostate Cancer and Castration Resistant Prostatic Cancer, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT03248570 is a Phase 2 study of Metastatic Prostate Cancer and Castration Resistant Prostatic Cancer that has completed, run by University of California, San Francisco. The registered enrollment target is 26 participants, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03248570, a Phase 2 study of Metastatic Prostate Cancer and Castration Resistant Prostatic Cancer, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Chemotherapy
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03248570
The ClinicalTrials.gov registry entry for NCT03248570 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (86% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03248570 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03248570 about?
NCT03248570 is a clinical study titled "Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects". This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.
What is the current status of trial NCT03248570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2018-02-20. Estimated completion is 2023-09-28.
What conditions does trial NCT03248570 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer, Castration Resistant Prostatic Cancer.
What interventions are being tested in trial NCT03248570?
The interventions under investigation include: Pembrolizumab (DRUG), Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03248570?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03248570 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 2
-
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
RECRUITING · Phase 2
-
A Study of Tarlatamab for People With Prostate Cancer
RECRUITING · Phase 2
-
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RECRUITING · Phase 2
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Prostate Cancer
All registered trials for this condition
Castration Resistant Prostatic Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.